Bat plasminogen activator: Desmoteplase - From bat to bench to bedside of stroke victims

Toxins and Hemostasis: From Bench to Bedside

Volumn , Issue , 2011, Pages 393-407

  Söhngen, Wolfgang ^a   Petersen, Karl Uwe ^a   Söhngen, Mariola ^a  

^a PAION Deutschland GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920153718     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-9295-3_23     Document Type: Chapter

References (46)

1. Belwood, J.J., Morton, P.A., 1991. Vampires: The real story. The truth about the bats people love to hate is even more fascinating than the myths. Bats 9, 11-16.
2. Benchenane, K., López-Atalaya, J.P., Fernandez-Monreal, M., Touzani, O., Vivien, D., 2004. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 27, 155-160.
3. Benchenane, K., Castel, H., Boulouard, M., Bluthé, R., Fernandez-Monreal, M., Roussel, B.D., López-Atalaya, J.P., Butt-Gueulle, S., Agin, V., Maubert, E., Dantzer, R., Touzani, O., Dauphin, F., Vivien, D., Ali, C., 2007. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J. Cell. Sci. 120, 578-585.
4. Bergum, P.W., Gardell, S.J., 1992. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. A kinetic analysis. J. Biol. Chem. 267, 17726-17731.
5. Bringmann, P., Gruber, D., Liese, A., Toschi, L., Krätzchmar, J., Schleuning, W.D., Donner, P., 1995. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J. Biol. Chem. 270, 25596-25603.
6. Busch, E., Krüger, K., Fritze, K., Allegrini, P.R., Hoehn-Berlage, M., Hossmann, K.A., 1997. Blood-brain barrier disturbances after rt-PA treatment of thromboembolic stroke in the rat. Acta Neurochir. Suppl. 70, 206-208.
7. Collen, D., 1996. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 93, 857-865.
8. Epple, G., Schleuning, W.D., Kettelgerdes, G., Kottgen, E., Gessner, R., Praus, M., 2004. Prion protein stimulates tissue-type plasminogen activator-me diated plasmin generation via a lysinebinding site on kringle 2. J. Thromb. Haemost. 2, 962-968.
9. Fanne, R.A., Nassar, T., Yarovoi, S., Rayan, A., Lamensdorf, I., Karakoveski, M., Vadim, P., Fanne, R.A., Jamal, M., Cines, D.B., Al-Roof Higazi, A., 2010. Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology 58, 972-980.
10. Fernández-Monreal, M., López-Atalaya, J.P., Benchenane, K., Cacquevel, M., Dulin, F., Le Caer, J.P., Rossier, J., Jarrige, A.C., Mackenzie, E.T., Colloc'h, N., Ali, C., Vivien, D., 2004. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J. Biol. Chem. 279, 50850-508506.
11. Fredriksson, L., Ehnman, M., Fieber, C., Eriksson, U., 2005. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J. Biol. Chem. 280, 26856-26862.
12. Furlan, A.J., Eyding, D., Albers, G.W., Al-Rawi, Y., Lees, K.R., Rowley, H.A., Sachara, C., Soehngen, M., Warach, S., Hacke, W., DEDAS Investigators, 2006. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37, 1227-1231.
13. Gulba, D.C., Praus, M., Witt, W., 1995. DSPA alpha - properties of the plasminogen activators of the vampire bat Desmodus rotundus. Fibrinolysis 9(Suppl.), 91-96.
14. Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D, . Larrue, V., Bluhmki, E., Davis, S., Donnan, G., Schneider, D., Diez-Tejedor, E., Trouillas, P., 1998. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet, 352: 1245-1251.
15. Hacke, W., Albers, G., Al-Rawi, Y., Bogousslavsky, J., Davalos, A., Eliasziw, M., Fischer, M., Furlan, A., Kaste, M., Lees, K.R., Soehngen, M., Warach, S., for The DIAS Study Group, 2005. The desmoteplase in acute ischemic stroke trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36, 66-73.
16. Hacke, W., Furlan, A.J., Al-Rawi, Y., Davalos, A., Fiebach, J.B., Gruber, F., Kaste, M., Lipka, L.J., Pedraza, S., Ringleb, P.A., Rowley, H.A., Schneider, D., Schwamm, L.H., Leal, J.S., Söhngen, M., Teal, P.A., Wilhelm-Ogunbiyi, K., Wintermark, M., Warach, S., 2009. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 8, 141-50.
17. Kassner, A., Roberts, T.P., Moran, B., Silver, F.L., Mikulis, D.J., 2009. Recombinant tissue plasminogen activator increases blood-brain barrier disruption in acute ischemic stroke: An MR imaging permeability study. Am. J. Neuroradiol. 30, 1864-1869.
18. Keyt, B.A., Paoni, N.F., Refino, C.J., Berleau, L., Nguyen, H., Chow, A., Lai, J., Peña, L., Pater, C., Ogez, J., Etcheverry, T., Botstzein, D., Bennett, W.F., 1994. A faster-acting and more potent form of tissue plasminogen activator. Proc. Natl. Acad. Sci. U.S.A. 91, 3670-3674.
19. Kidwell, C.S., Latour, L., Saver, J.L., Alger, J.R., Starkman, S., Duckwiler, G., Jahan, R., Vinuela, F., UCLA Thrombolysis Investigators, Kang, D.W., Warach, S., 2008. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc. Dis. 25, 338-343.
20. Krätzschmar, J., Haendler, B., Langer, G., Boidol, W., Bringmann, P., Alagon, A., Donner, P., Schleuning, W.D., 1991. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 105, 229-237.
21. Kruithof, E.K., Schleuning, W.D., 2004. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator. Thromb. Haemost. 92, 559-567.
22. Liberatore, G.T., Samson, A., Bladin, C., Schleuning, W.D., Medcalf, R.L., 2003. Vampire bat salivary plasminogen activator (desmoteplase): A unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 34, 537-543.
23. López-Atalaya, J.P., Roussel, B.D., Ali, C., Maubert, E., Petersen, K.-U., Berezowski, V., Cecchelli, R., Orset, C., Vivien, D., 2007. Recombinant Desmodus rotundus salivary plasminogen activator (desmoteplase) crosses the blood-brain barrier through a LDL receptorrelated protein (LRP)-dependent mechanism without exerting neurotoxic effects. Stroke 38, 1036-1043.
24. López-Atalaya, J.P., Roussel, B.D., Levrat, D., Parcq, J., Nicole, O., Hommet, Y., Benchenane, K., Castel, H., Leprince, J., van To, D., Bureau, R., Rault, S., Vaudry, H., Petersen, K.-U., Santos, J.S., Ali, C., Vivien, D., 2008. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J. Cereb. Blood Flow Metab. 28, 1212-1221.
25. Multicenter Acute Stroke Trial-Europe Study Group, 1996. Thrombolytic therapy with streptokinase in acute ischemic stroke. N. Engl. J. Med. 335, 145-150.
26. Muschick, P., Zeggert, D., Donner, P., Witt, W., 1993. Thrombolytic properties of Desmodus (vampire bat) salivary plasminogen activator DSPA alpha1, alteplase and streptokinase following intravenous bolus injection in a rabbit model of carotid artery thrombosis. Fibrinolysis 7, 284-290.
27. NINDS. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 33, 1581-1587.
28. Petersen, K.-U., 2007. Thrombolytics - A field in development. Riv. It. Neurobiologia 53, 7-14.
29. Reddrop, C., Moldrich, R.X., Beart, P.M., Farso, M., Liberatore, G.T., Howells, D.W., Petersen, K.-U., Schleuning, W.D., Medcalf, R.L., 2005. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 36, 1241-1246.
30. Renatus, M., Stubbs, M.T., Huber, R., Bringmann, P., Donner, P., Schleuning, W.D., Bode, W., 1997. Catalytic domain structure of vampire bat plasminogen activator: A molecular paradigm for proteolysis without activation cleavage. Biochemistry 36, 3483-3493.
31. Research Report A315, 1992. Lysis of human plasma and whole blood clots in vitro by ZK 152 387 (DSPA alpha1), ZK 153 786 (DSPA alpha2), ZK 155 278 (DSPA beta), ZK 153 858 (alteplase), ZK 130 932 (scu-PA), ZK 113 905 (urokinase), and ZK 156 552 (anistreplase). (PAION, data on file).
32. Research Report PN01 PCD 00002/01, 2001. Comparing the therapeutic benefit of desmoteplase, reteplase, and alteplase in a rat model of embolic middle cerebral artery (MCA) occlusion. (PAION, data on file).
33. Schering Report, Gulba, D., 2002. rDSPA alpha1 in the establishment of early patency in myocardial infarction. (PAION, data on file).
34. Schleuning, W.D., Alagon, A., Boidol, W., Bringmann, P., Petri, T., Krätzschmar, J., Haendler, B., Langer, G., Baldus, B., Witt, W., Donner, P., 1992. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Ann. N. Y. Acad. Sci. 667, 395-403.
35. Schleuning, W.D., 2001. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): A thrombolytic drug optimized by natural selection. Haemostasis 31, 118-122.
36. Stewart, R.J., Fredenburgh, J.C., Weitz, J.I., 1998. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J. Biol. Chem. 273, 18292-18299.
37. Sobel, B.E., Geltman, E.M., Tiefenbrunn, A.J., Jaffe, A.S., Spadaro, J.J. Jr., Ter-Pogossian, M.M., Collen, D., Ludbrook, P.A., 1984. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. Circulation 69, 983-690.
38. Su, E.J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., Gao, Y., Pietras, K., Mann, K., Yepes, M., Strickland, D.K., Betsholtz, C., Eriksson, U., Lawrence, D.A., 2008. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 14, 731-737.
39. Su, E.J., Fredriksson, L., Schielke, G.P., Eriksson, U., Lawrence, D.A., 2009. Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J. Thromb. Haemost. 7(Suppl. 1), 155-158.
40. Tebbe, U., Bramlage, P., Graf, A., Lechleitner, P., Bode, C., Riess, F.C., Clemens, N., Al-Rawi, Y., Konstantinides, S., Goldhaber, S.Z., 2009. Desmoteplase in acute massive pulmonary thromboembolism. Thromb. Haemost. 101, 557-562.
41. Toschi, L., Bringmann, P., Petri, T., Donner, P., Schleuning, W.D., 1998. Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators. Eur. J. Biochem. 252, 108-112.
42. Tsirka, S.E., 2002. Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem. Soc. Trans. 30, 222-225.
43. Yepes, M., Sandkvist, M., Moore, E.G., Bugge, T.H., Strickland, D.K., Lawrence, D.A., 2003. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112, 1533-1540.
44. Yepes, M., Roussel, B.D., Ali, C., Vivien, D., 2009. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci. 32, 48-55.
45. Witt, W., Balds, B., Bringmann, P., Cashon, L., Donner, P., Schleuning, W.D., 1992. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 79, 1213-1217.
46. Witt, W., Maass, B., Baldus, B., Hildebrand, M., Donner, P., Schleuning, W.D., 1994. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 90, 421-426.